Evonik's Strategic Position Amid Trade Policy Shifts

Evonik's share price consolidates after rally. CEO sees trade barriers as strategic opportunity. Barclays cites methionine market shifts and energy security for Overweight rating.

The recent rally in Evonik's share price has been notable, with gains of approximately twelve percent since late March propelling the stock to a fresh six-month peak. However, momentum stalled at the start of the week as investors reacted to new U.S. tariffs and engaged in profit-taking. CEO Christian Kullmann has framed the evolving global trade landscape not merely as a risk, but as a potential strategic opening for the German specialty chemicals group.

Analysts point out that the preceding weeks' advance was driven more by sector rotation than a fundamental turnaround. As turbulence hit highly-valued technology stocks, capital flowed into more modestly-priced value equities, with chemical sector names like Evonik benefiting disproportionately. A period of consolidation was widely anticipated.

A Dual-Edged Trade Environment

Leadership at Evonik has highlighted the nuanced impact of trade barriers. With around 80% of the products it sells in the United States also manufactured there, new tariffs could disadvantage Chinese competitors in that market, potentially allowing Evonik to capture greater market share. Interim CFO Claus Rettig noted that provisions related to the tense trade environment have led to a reclaimable amount in the "lower double-digit millions of euros." While not an existential threat, this adjustment signals customer apprehension.

Barclays maintains an "Overweight" rating on the stock with a price target of 17 euros. The bank's upgrade in March was based on two key premises. First, structural shifts are occurring in the methionine market. Supply constraints stemming from the conflict involving Iran are pressuring Asian producers, leading global buyers to seek non-Asian sources—a trend from which Evonik stands to gain. Methionine prices have already risen in both China and Europe. Second, Evonik has secured about 80% of its energy needs through pre-arranged contracts, significantly above the industry average. Consequently, Barclays raised its 2026 EBITDA estimate for the company to 1.89 billion euros, which is three percent above the current market consensus.

Transformation, Portfolio Pruning, and Leadership

The company's "Evonik Tailor Made" transformation program remains on track. The initiative aims to achieve annual savings of 400 million euros by the end of 2026, largely through a global workforce reduction of up to 2,000 positions, with roughly 1,500 of those in Germany. The strategic plan through 2027 rules out major acquisitions, focusing instead on debt reduction and the divestment of its Syneqt and Oxeno units. Barclays sees potential upside in these sales; given recent transactions in chemical infrastructure services, Syneqt—which generates roughly 200 million euros in EBITDA—could command a higher valuation multiple than Evonik's current implied group valuation.

Attention now turns to the Annual General Meeting on June 3, which will be held virtually from Essen. Alongside the dividend vote, the agenda includes filling the CFO position, which will become vacant in September 2025. Shareholders are set to receive a dividend of 1.00 euro per share for 2025, down from 1.17 euros the previous year. Starting in 2026, Evonik plans a payout ratio of 40% to 60% of adjusted group net income. Management is targeting an adjusted EBITDA range of 1.7 to 2.0 billion euros for 2026, broadly aligning with analyst expectations of around 1.8 billion euros. The upcoming first-quarter results, expected before the AGM, will provide the next crucial test for these financial projections.